Severe Hepatic Sinusoidal Obstruction Syndrome in a Child Receiving Vincristine, Actinomycin-D, and Cyclophosphamide for Rhabdomyosarcoma: Successful Treatment with Defibrotide
Aery Choi, Young Kyung Kang, Sewon Lim, Dong Ho Kim, Jung Sub Lim, Jun Ah Lee
Cancer Res Treat. 2016;48(4):1443-1447. Published online 2016 Mar 30 DOI: https://doi.org/10.4143/crt.2016.096
Citations to this article as recorded by 
Treatment of Sinusoidal Obstruction Syndrome With Defibrotide in Pediatric Cancer Patients Following Nontransplant-associated Chemotherapy: A Case Report and Review of the Literature
Marc R. Lawrence, Mylène Bassal, Raveena Ramphal, Donna L. Johnston
Journal of Pediatric Hematology/Oncology.2022; 44(3): e788. CrossRef
Indispensable role of microbes in anticancer drugs and discovery trends
Ridam Kapoor, Anamika Saini, Deepika Sharma
Applied Microbiology and Biotechnology.2022; 106(13-16): 4885. CrossRef
Caspase inhibitor z-VAD-FMK increases the survival of hair cells after Actinomycin-D-induced damage in vitro
Huimin Chang, Fei Sun, Keyong Tian, Weilong Wang, Ke Zhou, Dingjun Zha, Jianhua Qiu
Neuroscience Letters.2020; 732: 135089. CrossRef
Adjuvant recombinant thrombomodulin therapy for hepatopathy induced by vincristine, actinomycin D, and cyclophosphamide in pediatric rhabdomyosarcoma: A case report
Tetsuko Kobayashi, Maiko Noguchi, Hideki Nakayama, Reiji Fukano, Shouichi Ohga
Molecular and Clinical Oncology.2019;[Epub] CrossRef
“Pre‐emptive strike”—the case for early treatment of hepatic sinusoidal obstruction syndrome with defibrotide
Revathi Rajagopal, Marianne B. Phillips, Nicholas G. Gottardo
Pediatric Blood & Cancer.2018;[Epub] CrossRef
Cyclophosphamide/dactinomycin/vincristine
Reactions Weekly.2017; 1637(1): 75. CrossRef